Genetic Engineering News
scienceCenter
Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancertranslating…
1 min readUnknownGenetic Press Ltd
The Phase I dose escalation trial of ACESOT-1051 (NCT06260514) will accelerate its patient enrollment, with Aprea planning to more than triple its number of active clinical sites for the study from three to 10. The expansion is expected to accelerate the pace of clinical data…